Target pattern recognition by complement proteins of the classical and alternative pathways

Advances in Experimental Medicine and Biology

Volumn 653, Issue , 2009, Pages 117-128

  Kang, Yu Hoi ^b   Tan, Lee Aun ^b   Carroll, Maria V ^b   Gentle, Madeleine E ^b   Sim, Robert B ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1Q RECEPTOR; COMPLEMENT RECEPTOR; IMMUNOGLOBULIN; PROPERDIN; UNCLASSIFIED DRUG; COMPLEMENT 1Q RECEPTOR; MEMBRANE PROTEIN;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; ANIMAL; CHEMISTRY; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; REVIEW;

ANIMALIA;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; COMPLEMENT C1Q; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; HUMANS; IMMUNOGLOBULINS; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; PROPERDIN; RECEPTORS, COMPLEMENT;

EID: 70349598981     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-0901-5_8     Document Type: Article

References (88)

1. Walport MJ.Complement. First of two parts. N Engl J Med 2001; 344:1058-66.
2. Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344:1140-4.
3. Mayilyan KR, Kang YH, Dodds AW et al. The complement system in innate immunity. In: Heine H, ed. Innate Immunity of Plants, Animals and Humans (Nucleic acids and molecular biology vol 21). Heidelberg: Springer, 2008:219-236.
4. Sim RB, Dodds AW The complement system: an introduction. In Dodds AW, Sim RB, eds. Complement, a Practical Approach. Oxford: Oxford University Press, 1997:1-18.
5. Sim RB, Reid KBM. C1: Molecular interaction with activating systems. Immunol Today 1991; 12:307-311.
6. Sim RB, Malhotra R. Interactions of carbohydrates and lectins with complement. Biochem Soc Trans 1994; 22:106-111. (Pubitemid 24072398)
7. Dodds AW, Sim RB, Porter RR et al. Activation of the first component of human complement (CI) by antibody-antigen aggregates. Biochem J 1978; 175:383-390. (Pubitemid 9060097)
8. Krarup A, Mitchell DA, Sim RB. Recognition of acetylated oligosaccharides by human L-ficolin. Immunol Lett 2008; 118:52-6.
9. Sim RB, Tsiftsoglou SA. Proteases of the complement system. Biochem Soc Trans 2004; 32:21-27. (Pubitemid 38283006)
10. Kemper C, Hourcade DE. Properdin: New roles in pattern recognition and target clearance. Mol Immunol 2008; 45:4048-56.
11. Sim RB, Moffatt BE, Shaw JM et al. Complement control proteins and receptors: from FH to CR4. In: Reid KB, Sim RB, eds. Molecular Aspects of Innate and Adaptive Immunity. Cambridge: Royal Society of Chemistry, 2008:84-104.
12. Reid KB, Porter RR, Subunit composition and structure of subcomponent Clq of the first component of human complement. Biochem J 1976,155:19-23.
13. Knobel HR, Villiger W, Isliker H. Chemical analysis and electron microscopy studies of human Clq prepared by different methods. Eur J Immunol 1975; 5:78-82.
14. Reid KB, Sim RB, Faiers AP. Inhibition of the reconstitution of the haemolytic activity of the rirst component of human complement by a pepsin-derived fragment of subcomponent Clq. Biochem J 1977; 161:239-245. (Pubitemid 8025727)
15. Sim RB, Arlaud GJ, Colomb MG. C1-inhibitor-dependent dissociation of human complement component Cl bound to immune complexes. Biochem J 1979; 179:449-457. (Pubitemid 9216092)
16. Sim RB, Arlaud GJ, Colomb MG. Kinetics of reaction of human C1-inhibitor with the human complement system proteases C1r and C1s. Biochim Biophys Acta 1980; 612:433-449. (Pubitemid 10076173)
17. Colten HR, Gordon JM, Borsos T et al. Synthesis of the first component of human complement in vitro. J Exp Med 1968; 128:595-603.
18. Morris KM, Colten HR, Bing DH. The first component of complement. A quantitative comparison of its biosynthesis in culture by human epithelial and mesenchymal cells. J Exp Med 1978; 148:1007-1014.
19. Schwaeble W, Schafer MK, Petry F et al. Follicular dendritic cells, interdigitating cells, and cells of the monocyte-macrophage lineage are the Clq-producing sources in the spleen. Identification of specific cell types by in situ hybridization and immunohistochemical analysis. J Immunol 1995; 155:4971-4977
20. Whaley K. Biosynthesis of the complement components and the regulatory proteins of the alternative complement pathway by human peripheral blood monocyres. J Exp Med 1980; 151:501-514 .
21. Gulati P,Lemercier C, Guc D et al. Regulation of the synthesis of Cl subcomponents and C1-inhibitor. Behring Inst Mitt 1993; 93:196-203.
22. Tseng Y, Zavodszky P, Schumaker VN. The human complement Cl complex has a picomolar dissociation constant at room temperature. J Immunol 1997; 158:937-44. (Pubitemid 127492674)
23. Schumaker VN, Zavodszky P, Poon PH. Activation of the first component of complement. Annu Rev Immunol 1987; 5:21-42.
24. Bindon CI, Hale G, Waldmann H. Complement activation by immunoglobulin does not depend solely on Clq binding. Eur J Immunol 1990; 20:277-81. (Pubitemid 20082394)
25. Bindon CI, Hale G, Waldmann H. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur J Immunol 1988;18:1507-14. (Pubitemid 18269332)
26. Brüggemann M, WiUiams GT, Bindon CI et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987;166:1351-61. (Pubitemid 18051427)
27. Sim RB ed. Activators and Inhibitors of Complement. Dordrecht: K1uwer, 1993.
28. Roumenina L, Bureeva S, Kantardjiev A et al. Complement Clq-target proteins recognition is inhibited by electric moment effecrors. J Mol Recognit 2007; 20:405-415.
29. Arnold IN, Wormald MR, Sim RB et al. The impact of g1ycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25:21-50. (Pubitemid 46697901)
30. Duncan AR, Winter G. The binding site for Clq on IgG. Nature 1988; 332:738-742.
31. Idusogie EE, Presta LG, Gazzano-Santoro H et al. Mapping of the Clq binding site on rituxan, a chimeric antibody with a human IgGl Fc. J Immunol 2000; 164:4178-4184. (Pubitemid 30215076)
32. Perkins S J, Nealis AS, Sutton BJ et al. Solution structure of human and mouse immunoglobulin M by synchrotron X-ray scattering and molecular graphics modelling. A possible mechanism for complement activation. J Mol Biol 1991; 221:1345-1366. (Pubitemid 121003457)
33. Païdassi H, Tacnet-Delorme P, Lunardi T et al. The lectin-like activiry of human Clq and its implication in DNA and apoptotic cell recognition. FEBS Lett 2008; 582:3111-3116.
34. Loos M, Bitter-Suermann D, Dierich MP. Interaction of the first (Cl), the second (C2) and the fourth (C4) component of complement with different preparations of bacterial Iipopolysaccharides and with lipid A. J Immunol 1974; 112:935-950.
35. Zohair A, Chesne S, Wade RH et al. Interaction between complement subcomponent Clq and bacterial Iipopolysaccharides. Biochem J 1989; 257:865-873. (Pubitemid 19050144)
36. Latsch M, Mollerfeld J, Ringsdorf H et al. Studies on the interaction of Clq, a subcomponent of the first component of complement, with porins from Salmonella minnesota incorporated into artificial membranes. FEBS Lett 1990; 276:201-204.
37. Van Schravendijk MR, Dwek RA. Interaction of Clq with DNA. Mol Immunol 1982; 19:1179-1184.
38. Kovacsovics T, Tschopp J, Kress A et al. Antibody-independent activation of Cl, the first component of complement, by cardiolipin. J Immunol 1985; 135:2695-2703.
39. Tan LA, Sim RB. Complement activation by phospholipids (PL). Mol Immunol 2001; 38:122-122.
40. Païdassi H, Tacnet-Delorme P, Garlatti V et al. Clq binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition. J Immunol 2008; 180:2329-38.
41. Sorensen IJ, Nielsen EH, Andersen O et al 1996. Binding of complement proteins Clq and C4bp to serum amyloid P component (SAP) in solid contra liquid phase. Scand J Immunol 1996; 44:401-409.
42. McGrath FD, Brouwer MC, Arlaud GJ et al. Evidence that complement protein Clq interacts with C-reactive protein through its globular head region. J Immunol 2006; 176:2950-2957.
43. Agrawal A, Shrive AK, Greenhough TJ et al. Topology and structure of the Clq-binding site on C-reactive protein. J Immunol 2001; 166:3998-4004. (Pubitemid 32224928)
44. Bickerstaff MC, Botto M, Hutchinson WL et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999; 5:694-7. (Pubitemid 29289434)
45. Hicks PS, Saunero-Nava L, Du Clos TW et al. Serum amyloid P component binds to histones and activates the classical complement pathway. J Immunol 1992; 149:3689-94.
46. Boackle RJ, Connor MH, Vesely J. High molecular weight nonimmunoglobulin salivary agglutinins (NIA) bind ClQ globular heads and have the potential to activate the first complement component. Mol Immunol 1993; 30:309-19.
47. Ebenbichler CF, Thielens NM, Vornhagen M et al 1991. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med 1991; 174:1417-1424.
48. Laos M, Clas F, Fischer W. Interaction of purified Iipoteichoic acid with the classical complement pathway. Infect Immun 1986; 53:595-9. (Pubitemid 16053181)
49. Carroll MY, Lack N, Krarup A et al. Multiple routes of complement activation by mycobacterium bovis BCG. Molec Immunol 2008; 45:4168-4168.
50. Sim RB, Kishore U, Villiers CL et al. Clq binding and complement activation by prions and amyloids. Immunobiology 2007; 212:355-262.
51. Salvador-Morales C. Flahaut E, Sim E et al. Carbon nanotubes activate the human serum complement system. Molec Immunol 2006; 43:193-201. (Pubitemid 41384125)
52. Nilsson UR, Lam O, Nilsson B et al. Modification of the complement binding properties of polystyrene: effects of end-point heparin attachment. Scand J Immunol 1993; 37:349-54. (Pubitemid 23070511)
53. Cliquet F, Cuilliere ML, Montagne P et al. Interactions of complement fraction Clq, fibronectin. and immunoglobulin G with polyacrylic microparricles used as solid-phase in immunoassay. J Biomed Mater Res 1993; 27:587-97. (Pubitemid 23118722)
54. Hamad OA, Ekdahl KN, Nilsson PH et al. Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J Thromb Haemost 2008; 6:1413-21. (Pubitemid 352016323)
55. Kirschfink M, Blase L, Engelmann S et al. Secreted chondroitin sulfate proteoglycan of human B cell lines binds to the complement protein Clq and inhibits complex formation of C1. J Immunol 1997; 158:1324-31. (Pubitemid 127469958)
56. Almeda S, Rosenberg RD, Bing DH. The binding properties of human complement component Clq. Interaction with mucopolysaccharides. J Biol Chem 1983; 258:785-91. (Pubitemid 13139326)
57. Krumdieck R, Höök M. Rosenberg LC et al. The proteoglycan decorin binds Clq and inhibits the activity of the Cl complex. J Immunol 1992; 149:3695-701.
58. Stevens B. Allen NJ, Vazquez LE, et al. The classical complement cascade mediates CNS synapse elimination. Cell 2007; 131:1164-1178. (Pubitemid 350235022)
59. Mayilyan KR, Weinberger DR, Sim RB. The complement system in schiwphrenia. Drug News Perspect 2008; 21 :200-10.
60. Navratil JS, Watkins SC, Wisnieski JJ et al. The globular heads of Clq specifically recognize surface blebs of apoptotic vascular endothelial cells. J Immunol 2001; 166:3231-3238.
61. Nauta AJ, Trouw L, Daha MR et al 2002. Direct binding of Clq to apoptotic cells and cell blebs induces complement activation. Eur J Immunol 2002; 32:1726-1732.
62. Ogden CA, deCathelineau A, Hoffmann PR et al 2001. Clq and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinoeytosis and uptake of apoptotic cells. J Exp Med 2001; 194:781-790.
63. Nauta AJ. Castellano G, Xu w et al. Opsonization with Clq and mannose-binding lectin targets apoptotic cells to dendritic cells. J Immunol 2004; 173:3044-3050. (Pubitemid 39142010)
64. Nauta AJ. Daha MR, van Kooten C et al. Recognition and clearance of apoptotic cells: a role for complement and pentraxins. Trends Immunol 2003; 24:148-153.
65. Pickering MC. Botto M, Taylor PR et al. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000; 76:227-240.
66. Botto M, Dell'Agnola C, Bygrave AE et al. Homozygous Clq deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998; 19:56-59. (Pubitemid 28242023)
67. Casciola-Rosen LA, Anhalt G. Rosen A. Autoantigens targeted in systemic lupus etyrhematosus are clustered in two populations of surface structures on apoptotic keratinoeytes. J Exp Med 1994; 179:1317-1324.
68. Gaboriaud C, Juanhuix J, Gruez A et al. The crystal structure of the globular head of complement protein Clq provides a basis for its versatile recognition properties. J Biol Chem 2003; 278:46974-46980.
69. Corpet F. Multiple sequence alignment with hierarchical clustering. Nucl Acids Res 1988; 16:10881-10890.
70. Kishore U. Strong P, Perdikoulis MV et al. A recombinant homorrimer, composed of the alpha helical neck region of human surfactant protein D and Clq B chain globular domain, is an inhibitor of the classical complement pathway. J Immunol 2001; 166:559-65. (Pubitemid 32038477)
71. Kishore U, Leigh LE, Eggleton P et al. Functional characterization of a recombinant form of the C-terminal, globular head region of the B-chain of human serum complement protein, Clq. Biochem J 1998; 333:27-32. (Pubitemid 28342488)
72. Kishore U, Gupta SK, Perdikoulis MY et al. Modular organization of the carboxyl-terminal, globular head region of human Clq A. B. and C chains. J Immunol 2003; 171:812-20. (Pubitemid 36871392)
73. Kojouharova MS, Gadjeva MG, Tsacheva IG et al. Mutational analyses of the recombinant globular regions of human CIq A, B, and C chains suggest an essential role for arginine and histidine residues in the Clq-IgG interaction. J Immunol 2004; 172:4351-8. (Pubitemid 38375250)
74. Roumenina LT, Ruseva MM, Zlatarova A et al. Interaction of Clq with IgGl, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human Clq A, B, and C chains. Biochemistry 2006; 45:4093-104.
75. Gadjeva MG, Rouseva MM, Zlatarova AS et al. Interaction of Human Clq with IgG and IgM: Revisited. Biochemistry 2008; 47(49):13093-102.
76. 2+ in the electrostatic stability and the functional activity of the globular domain of human Clq. Biochemistry 2005; 44:14097-109. (Pubitemid 41534668)
77. Sim, RB, Moestrup SK, Stuart GR et al. Interaction of Clq and the collectins with the potential receptors calreticulin (cClqRlcollectin receptor) and megalin. Immunobiology 1998; 199:208-215.
78. Malhotra R, Thiel S, Reid KB et al. Human leukocyte Clq receptor binds other soluble proteins with collagen domains. J Exp Med 1990; 172:955-9. (Pubitemid 20301242)
79. Malhotra R, Laursen SB, Willis AC et al Localization of the receptor-binding site in the collectin family of proteins. Biochem J 1993; 293:15-9. (Pubitemid 23223140)
80. Guan E, Robinson SL,Goodman EB et al. Cell-surface protein identified on phagocytic cells modulates the Clq-mediated enhancement of phagocytosis. J Immunol 1994; 152:4005-4011.
81. McGreal E.,Ikewaki N, Akatsu H et al. Human ClqRp is identical with CD93 and the mNI-11 antigen but does not bind Clq. J Immunol 2002; 168:5222-5228.
82. Klickstein L, Barbashov SF, Liu T et al. Complement receptor type 1 (CR1, CD35) is a receptor for Clq. Immunity 1997; 7:345-353.
83. van den Berg RH., Faber-Krol MC, Sim RB et al 1998. The first subcomponent of complement, Clq, triggers the production of IL-8, IL-6, and monocyte chemoatrtactant peptide-l by human umbilical vein endothelial cells. J Immunol 1998; 161:6924-31.
84. Dodds AW. The evolution of complement systems. In: Reid KB, Sim RB, eds. Molecular Aspects of Innate and Adaptive Immunity. Cambridge: Royal Society of Chemistry, 2008:27-48.
85. Matsushita M, Matsushita A, Endo Y et al. Origin of the classical complement pathway: Lamprey orthologue of mammalian Clq acts as a lectin. Proc Natl Acad Sci USA 2004; 101:10127-31. (Pubitemid 38891206)
86. Yu Y, Huang H, Wang Y et al. A novel Clq family member of amphioxus was revealed to have a partial function of vertebrate Clq molecule. J Immunol 2008; 181:7024-32.
87. Nolan KF, Schwaeble W, Kaluz S et al Molecular cloning of the cDNA coding for properdin, a positive regulator of the alternative pathway of human complement. Eur J Immunol 1991; 21:771-6.
88. Schwaeble W, Reid KB. Does properdin crosslink the cellular and the humoral immune response? Immunol Today 1999; 20:17-21. (Pubitemid 29136545)